The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Six start-ups bestowed with new ‘heart of pharma’ commendation in recognition of innovations advancing drug delivery and packagingWednesday 22nd January – Live from Porte De Versailles, ...

Six start-ups bestowed with new ‘heart of pharma’ at Pharmapack Europe: Our Bureau, Mumbai Thursday, January 23, 2025, 17:15 Hrs [IST] Pharmapack Europe 2025 taking place from ...

The FDA has approved Datroway (datopotamab deruxtecan) to treat adults with unresectable or metastatic, HR+, HER2- breast cancer who have received prior endocrine therapy and chemotherapy.

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has authorized Vabysmo® ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

National Resilience’s headcount reduction follows an announcement in February to expand its operations at the North Carolina site, including a new isolator filler to support vials and PFS.